The third quarter of 2024 brought a mix of gains and modest declines for the pharmaceutical industry’s top players ... Among ...
Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...
At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ ... deal for Immunomedics (with the drug ...
MarketBeat on MSN4d
Gilead's Stock Surge: What's Fueling the Momentum?Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...
Cantor Fitzgerald analyst Olivia Brayer maintained a Hold rating on Gilead Sciences (GILD – Research Report) yesterday and set a price ...
In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Gilead Sciences (GILD – Research Report), with ...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...
Zacks.com on MSN7d
Gilead Science to Report Q3 Earnings: What's in the Cards?Biotech giant Gilead Sciences, Inc. GILD is scheduled to report third-quarter 2024 results on Nov. 6, after market close. The ...
MAM received funding from Gilead Pharmaceuticals, Novartis, Johnson and Johnson, Citius Pharmaceuticals, Pliant Therapeutics, Gen1ELifesciences, and Calcimedica. Provenance and peer review: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback